Management of Hyperpigmentation in Darker Racial Ethnic Groups

被引:128
作者
Grimes, Pearl E. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA
关键词
FLUOCINOLONE ACETONIDE 0.01-PERCENT; TRIPLE-COMBINATION AGENT; GLYCOLIC ACID PEELS; OF-LIFE INSTRUMENT; STEM-CELL FACTOR; HYDROQUINONE; 4-PERCENT; AZELAIC ACID; POSTINFLAMMATORY HYPERPIGMENTATION; EXOGENOUS OCHRONOSIS; IN-VITRO;
D O I
10.1016/j.sder.2009.04.001
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Dyschromias, in particular hyperpigmentation, are major issues of concern for people of color. Pigmentary disorders such as melasma and postinflammatory hyperpigmentation (PIH) can cause psychological and emotional distress and can pose a negative impact on a person's health-related quality of life. The precise etiology of these conditions is unknown. Therapies for melasma and PIH target various points during the cycle of melanin production and degradation. Therapies for these conditions include topical agents and resurfacing procedures. Hydroquinone remains the gold standard of topical agents. Other efficacious agents include kojic acid, azelaic acid, mequinol, and retinoids. Cosmeceutical agents include licorice, arbutin, soy, N-acetyl glucosamine, and niacinamide. Resurfacing procedures that have been used to treat melasma and PIH include chemical peels, micro-dermabrasion, lasers, and intense pulsed light. These procedures are best used in combination with topical bleaching agents. Given the propensity of darker skin to hyperpigment, resurfacing procedures should be used with care and caution. Maximal results are best achieved with repetitive, superficial, resurfacing modalities. In addition, ultraviolet protective measures such as broad-spectrum sunscreens are fundamental to the successful management of these conditions. Semin Cutan Med Surg 28:77-85 (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:77 / 85
页数:9
相关论文
共 83 条
[1]  
Alexis AF, 2007, CUTIS, V80, P387
[2]   Topical liquiritin improves melasma [J].
Amer, M ;
Metwalli, M .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (04) :299-301
[3]   Development and validation of a quality of life instrument for cutaneous diseases [J].
Anderson, RT ;
Rajagopalan, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (01) :41-50
[4]   Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma:: Split-face design [J].
Angsuwarangsee, S ;
Polnikorn, N .
DERMATOLOGIC SURGERY, 2003, 29 (01) :59-64
[5]   THE TREATMENT OF MELASMA - 20-PERCENT AZELAIC ACID VERSUS 4-PERCENT HYDROQUINONE CREAM [J].
BALINA, LM ;
GRAUPE, K .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1991, 30 (12) :893-895
[6]   Development and validation of a health-related quality of life instrument for women with melasma [J].
Balkrishnan, R ;
McMichael, AJ ;
Camacho, FT ;
Saltzberg, F ;
Housman, TS ;
Grummer, S ;
Feldman, SR ;
Chren, MM .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (03) :572-577
[7]  
BALKRISHNAN R, BRIT J DERMATOLOGY, V149, P572
[8]  
Baumann L, 2006, CUTIS, V78, P2
[9]  
BISSETT DL, 2006, PIG CELL RES, V19, P373
[10]  
Bissett Donald L, 2006, J Cosmet Dermatol, V5, P309, DOI 10.1111/j.1473-2165.2006.00277.x